Form 4: Kymera Therapeutics Executive Trades Shares

Kymera Therapeutics Chief Business Officer Noah Goodman executed a series of stock transactions, including acquisitions and sales, on April 9th and 10th, 2026.

Summary

• Noah Goodman, Chief Business Officer at Kymera Therapeutics, Inc., reported transactions involving common stock on April 9th and 10th, 2026.
• On April 9th, 2026, Goodman acquired 2,500 shares of common stock at a price of $21.05 per share, totaling $52,625.
• Also on April 9th, Goodman disposed of a total of 8,264 shares of common stock through multiple transactions, with weighted average prices of $86.618 and $87.1109, and a separate sale of 2,500 shares at $89.
• On April 10th, 2026, Goodman sold an additional 2,000 shares at a weighted average price of $87.35.
• These transactions were conducted under a Rule 10b5-1 trading plan established on December 10, 2025.
• A portion of the sales on April 9th (3,094 shares and 2,670 shares) were to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant number of shares sold by a key executive, despite the transactions being executed under a pre-planned Rule 10b5-1 strategy and for tax withholding purposes.

Positives

• Acquisition of 2,500 shares at a price significantly lower than the sale prices, indicating potential for future gains.
• The transactions were executed under a pre-established Rule 10b5-1 trading plan, suggesting a structured and non-opportunistic approach to trading.
• The sale of shares to cover tax withholding obligations upon RSU vesting is a standard and expected event for executives.

Negatives

• Disposal of a significant number of shares (8,264 shares on April 9th and 2,000 shares on April 10th) by a key executive.
• The sales occurred at prices substantially higher than the acquisition price, indicating the executive may be realizing gains, potentially signaling a lack of strong short-term positive outlook from their perspective.

Risks

• Potential for further selling pressure if the Rule 10b5-1 plan continues to trigger sales.
• The executive's sales could be interpreted by the market as a lack of confidence in the company's immediate future, although the sales are part of a pre-planned strategy.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. However, the existence of a Rule 10b5-1 trading plan implies a structured approach to future stock transactions, the specifics of which are not detailed.

Management Comments

• Transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025.
• Shares sold represent those required to cover tax withholding obligations in connection with the vesting of RSUs, and such sales were automatic and not in the discretion of the reporting person.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, can sometimes be perceived negatively by the market. However, the context of RSU vesting and tax obligations is a common driver for such transactions among executives in the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: May interpret the executive's sales as a signal, potentially impacting short-term stock sentiment, though the planned nature of the sales mitigates this concern.
• Employees: The sale of shares to cover tax withholding on RSUs is a standard event for employees receiving equity compensation.
• Management: Demonstrates adherence to regulatory requirements and structured personal financial planning.

Next Steps

• The Rule 10b5-1 trading plan may continue to trigger future transactions as per its terms.
• The remaining portion of the stock option will vest in thirty-six (36) equal monthly installments, subject to continued employment.

Key Dates

Recommendation

The filing reports routine insider transactions under a pre-established plan for tax purposes, rather than indicating a fundamental change in the company's prospects or the executive's conviction. While the sales are notable, they do not provide sufficient information to warrant a strong buy or sell recommendation at this time.

Keywords

Form 4, SEC Filing, Kymera Therapeutics, KYMR, Noah Goodman, Stock Transaction, Insider Trading, Rule 10b5-1, Common Stock, RSU Vesting, Tax Withholding